Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics.
Phenobarbital is an effective and safe anticonvulsant drug introduced in clinical use in 1904. Its mechanism of action is the synaptic inhibition through an action on GABAA. The loading dose of phenobarbital is 20 mg/kg intravenously and the maintenance dose is 3 to 4 mg/kg by mouth. The serum concentration of phenobarbital is up to 40 µg/ml. Nonresponders should receive additional doses of 5 to 10 mg/kg until seizures stop. Infants with refractory seizures may have a serum concentration of phenobarbital of 100 µg/ml. Phenobarbital is metabolized in the liver by CYP2C9 with minor metabolism by CYP2C19 and CYP2E1. A quarter of the dose of phenobarbital is excreted unchanged in the urine. In adults, the half-life of phenobarbital is 100 hours and in term and preterm infants is 103 and 141 hours, respectively. The half-life of phenobarbital decreases 4.6 hours per day and it is 67 hours in infants 4 week old.
Via San Andrea 32, 56127 Pisa, Italy. pacificigm@tiscali.it.
Gian M
GM
Pacifici
D000927:Anticonvulsants / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010601:Pharmacology, Clinical; D010634:Phenobarbital / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology; D012640:Seizures / Q000188:drug therapy
D000927:Anticonvulsants; D010634:Phenobarbital